Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461Sherif S. Farag, Clara D. Bloomfield, Krzysztof Mrózek et al.|Blood|2006Cited by 332
11q23 balanced chromosome aberrations in treatment‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop†Clara D. Bloomfield, Susana C. Raimondi, Kellie J. Archer et al.|Genes Chromosomes and Cancer|2002Cited by 158
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance studyKrzysztof Mrózek, Ann‐Kathrin Eisfeld, Jessica Kohlschmidt et al.|Leukemia|2023Cited by 76
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W. Hoff, Yazan F. Madanat, William Blum et al.|Blood Advances|2024Cited by 29